Heat Biologics, Inc. (NASDAQ:HTBX) saw a large decrease in short interest in September. As of September 29th, there was short interest totalling 1,429,337 shares, a decrease of 33.8% from the September 15th total of 2,159,713 shares. Based on an average daily trading volume, of 312,051 shares, the days-to-cover ratio is currently 4.6 days. Currently, 4.2% of the company’s shares are sold short.
Several analysts have issued reports on the company. Noble Financial restated a “buy” rating on shares of Heat Biologics in a report on Tuesday, July 4th. ValuEngine cut Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Thursday, July 13th. Zacks Investment Research cut Heat Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Griffin Securities assumed coverage on Heat Biologics in a report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Heat Biologics has an average rating of “Hold” and an average price target of $2.13.
An institutional investor recently raised its position in Heat Biologics stock. KCG Holdings Inc. raised its stake in Heat Biologics, Inc. (NASDAQ:HTBX) by 35.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 175,769 shares of the biopharmaceutical company’s stock after acquiring an additional 45,831 shares during the quarter. KCG Holdings Inc. owned approximately 0.52% of Heat Biologics worth $156,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.74% of the company’s stock.
Shares of Heat Biologics (NASDAQ:HTBX) opened at 0.6366 on Friday. The firm has a 50-day moving average price of $0.62 and a 200 day moving average price of $0.64. The stock’s market capitalization is $22.78 million. Heat Biologics has a one year low of $0.46 and a one year high of $3.35.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/10/15/heat-biologics-inc-htbx-sees-significant-decrease-in-short-interest.html.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.